Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Perrigo adds acquisition VP Roop; CRN nets CHPA vet Al-Mondhiry as regulatory counsel; Jaeger joins NACDS; Vitacost gets new IT exec; and more People In Brief

You may also be interested in...



AHPA Offers Regulatory Suggestions: Health And Wellness Industry News

AHPA makes regulatory recommendations across supplement sector; CRN's Al-Mondhiry joins Amin Talati Upadhye; and Ismail moves from GOED.

People In Brief

NIH, FDA vet leads MusclePharm research

Who’s Hired? O’Brien To Replace Richards As Mayne Pharma CEO

Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel